MedTrace Logo

Study of FID-022 in Participants With Advanced Solid Tumors

NCT06694480 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-03

No results posted yet for this study

Summary

The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

FID-022

Advanced solid tumors

Sponsors & Collaborators

  • Fulgent Pharma LLC.

    lead INDUSTRY

Principal Investigators

  • Clinical Sites · Fulgent Pharma LLC.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-03
Primary Completion
2027-12-31
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06694480 on ClinicalTrials.gov